Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Request metadata listed "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc., trading as BASi).
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2008
Business Overview: The Company provides contract research services and research equipment to pharmaceutical, medical research, and biotechnology companies. Operations are divided into two segments: Contract Research Services (bioanalytical testing, preclinical safety, formulation) and Research Products (robotic sampling systems, analytical instruments). The Company exited the Phase I clinical trial market in June 2008 by selling its Baltimore Clinical Pharmacology Research Unit.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Total Revenue | $41.7 million | $39.8 million |
| Service Revenue | $32.9 million | $30.6 million |
| Product Revenue | $8.8 million | $9.2 million |
| Gross Profit | $15.3 million (36.8% margin) | $14.2 million (35.6% margin) |
| Operating Income | $2.8 million | $3.5 million |
| Net Income from Continuing Ops | $0.5 million | $1.6 million |
| Net Loss from Discontinued Ops | $(2.0) million | $(0.6) million |
| Net Income (Loss) | $(1.5) million | $0.9 million |
| Cash and Equivalents | $0.3 million | $2.8 million |
| Total Debt (Long-term + Current) | $11.2 million | $12.7 million |
| Revolving Line of Credit Used | $2.0 million | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.9% to $41.7 million. Service revenue grew 7.7% driven by bioanalytical and pharmaceutical analysis, while Product revenue declined 4.6% due to the non-renewal of a major Vetronics contract and fewer Culex system sales.
- Profitability Decline: Net income from continuing operations dropped 68.5% to $0.5 million. This was primarily due to a sharp increase in the effective tax rate (72.8% vs. 39.4%) caused by the inability to deduct UK facility losses against domestic income and additional expenses for uncertain tax positions.
- Discontinued Operations: The Company sold its Phase I clinical unit (CPRU) in June 2008. This resulted in a $0.5 million loss on disposal and a $2.0 million net loss from discontinued operations for the year, contributing to the overall net loss.
- Operating Expenses: Selling expenses surged 40.6% due to expanded sales efforts, new hires, and a $0.14 million impairment charge for patents with no revenue-generating products. General and administrative expenses rose 14.1% due to management hiring, stock compensation, and SOX compliance costs.
- Liquidity: Cash and cash equivalents decreased significantly from $2.8 million to $0.3 million. The Company utilized its revolving line of credit ($2.0 million outstanding) and repaid approximately $4.5 million in subordinated debt.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates spending approximately $2.0 million on capital assets in fiscal 2009. They believe cash from operations and existing credit facilities will fund requirements through September 30, 2009.
- Key Risks:
- Financing Constraints: Substantially all assets are encumbered as security for debt. The global credit crisis has negatively impacted the ability to obtain additional financing.
- Customer Concentration: Pfizer accounted for 7.4% of total revenue and 10.0% of trade receivables in 2008. Contracts are generally terminable on 30 days' notice.
- Listing Status: The Company faces potential delisting from NASDAQ if it fails to meet market value or equity requirements when procedures are reinstated in April 2009.
- Personnel Turnover: Significant turnover occurred in marketing and business development teams post-fiscal year-end, including the departure of the Chief Business Officer.
- Unusual Items:
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting related to an error in recording uncertain tax positions (FIN 48) upon adoption in 2007. This error caused a delay in the 10-K filing.
- Debt Covenant Breach: The Company was in breach of its tangible net worth requirement as of September 30, 2008. This was subsequently waived and amended by the lender in December 2008.
- Contingent Liability: Following the sale of the CPRU, the Company remains contingently liable for $0.8 million annually through 2015 if the buyer fails to meet lease commitments.
Investor Verification Checklist
- Debt Covenants: Verify the terms of the December 2008 waiver regarding the tangible net worth covenant and ensure no further breaches have occurred.
- Internal Controls: Confirm the implementation of the planned software in 2009 to address the material weakness in tax accounting.
- Liquidity Position: Monitor cash burn rates and the utilization of the $5 million revolving line of credit, given the low cash balance ($0.3 million).
- Customer Concentration: Assess the stability of the relationship with Pfizer (7.4% of revenue) and the impact of potential contract terminations.
- Discontinued Operations: Review the status of the contingent lease liability ($0.8 million/year) associated with the sold Baltimore facility.
- Stock Listing: Monitor the Company's ability to meet NASDAQ listing standards (market value or equity) by April 2009 to avoid delisting.